Herpes Zoster News and Research

RSS
Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
Takeda receives FDA approval for VELCADE sNDA to treat MM

Takeda receives FDA approval for VELCADE sNDA to treat MM

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex secures AU$6.25 million in expanded Series B funding

Adults with herpes zoster may face higher risk of multiple sclerosis

Adults with herpes zoster may face higher risk of multiple sclerosis

Gastroenterologists have limited knowledge of appropriate immunizations for IBD patients, study finds

Gastroenterologists have limited knowledge of appropriate immunizations for IBD patients, study finds

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Mary Ann Liebert to launch new 'Shingles and PHN' open access journal

Mary Ann Liebert to launch new 'Shingles and PHN' open access journal

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex fourth quarter net loss increases to $7.0 million

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Merck reports GAAP net income of $861 million for 2010

Merck reports GAAP net income of $861 million for 2010

Study finds recurrences of shingles prevalent in the immunocompetent population

Study finds recurrences of shingles prevalent in the immunocompetent population

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

FDA approves GRALISE Tablets for treatment of PHN

FDA approves GRALISE Tablets for treatment of PHN

Herpes zoster vaccine reduces risk of developing shingles by 55%

Herpes zoster vaccine reduces risk of developing shingles by 55%

Less than 7% of U.S. seniors get shingles vaccination

Less than 7% of U.S. seniors get shingles vaccination

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck announces initial results from ISENTRESS Phase III study in HIV-1